Plymouth Rock
Plymouth Rock Technologies Inc.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Plymouth (PRT) has completed its previously announced non-brokered private placement for gross proceeds of $1,684,000.00
  • Plymouth will use the net proceeds for commercialization of the company’s technologies, for working capital and debt settlement
  • PRT designs and manufactures next generation of threat detection solutions and Unmanned Aircraft Systems (UAS)
  • Plymouth Rock Technologies Inc. (PRT) is up 23.08 per cent, trading at C$0.08 per share at 1:29 pm ET

Plymouth (PRT) has completed its previously announced non-brokered private placement for gross proceeds of $1,684,000.00.

The company issued 33,680,000 units at $0.05 per unit. Each unit comprises of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at $0.10 for three years from the closing date.

Plymouth will use the net proceeds for commercialization of the company’s technologies, for working capital and for debt settlement.

The company paid finders’ fees of $142,400.00 cash and issued 2,848,000 finders’ b-warrants on a portion of the offering. Each finder’s b-warrant entitles the holder to purchase one common share at $0.10 for three years from closing date.

All securities issued are subject to a statutory four month hold period, expiring July 30, 2023.

About Plymouth Rock Technologies

PRT designs and manufactures next generation of threat detection solutions and Unmanned Aircraft Systems (UAS).

The company’s mission is to bring engineering-driven answers to the most critical problems that threaten safety. It works with government, law enforcement and military to innovate solutions for national security, defense and space systems.

Plymouth Rock Technologies Inc. (PRT) is up 23.08 per cent, trading at C$0.08 per share at 1:29 pm ET.

More From The Market Herald
Neuralink - Founder, Elon Musk.

" Neuralink brain chips approved for human trials

Elon Musk’s Neuralink, a brain implant firm, has received regulatory approval for U.S. human trials.

" @ the Bell: TSX snaps three-day losing skid

After a series of sessions in the red, Canada’s main stock index closed out Friday trading in the green as commodity prices nudged

" Marvell stock spikes 30 per cent on Q1 news  

Marvell Technology (NASDAQ:MRVL) shares rose more than 30 per cent Friday.